The clinical trial approval for the human diploid rabies vaccine developed by the Group has been recently obtained from the National Medical Products Administration. This product, as an iterative upgraded human diploid rabies vaccine, is featured with super highly-effective characteristics, and also marks a significant iterative upgrading in technology for the global rabies vaccine industry. Results from animal testing show that the Group’s human diploid rabies vaccine triggers a high level of antibodies that provide sufficient protection after immunization. Under the same dosage, the potency of the Group’s human diploid rabies vaccine is significantly higher than that of those marketed human diploid rabies vaccines.

Rabies is the most deadly disease in the world, with a fatality rate of nearly 100%. Currently, there is a lack of effective treatment for rabies in clinical practice, therefore, post-exposure prevention is crucial, and the main preventive measure is vaccination against human rabies.

Compared with the traditional Vero cell rabies vaccines, human diploid rabies vaccine uses human diploid cells instead of Vero cells, which are homologous to humans and have a natural safety advantage. The human diploid rabies vaccine currently available in the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, with higher product added value.

Compared with the traditional human diploid rabies vaccines of the first generation, the iterative-process highly-effective human diploid rabies vaccine developed by the Group has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in the traditional process. It has been optimized and innovated in the purification process with the product quality and safety significantly improved.

Compared with the number of traditional rabies vaccinations, this product developed by the Group can be vaccinated with either “five-needle approach”, “simple four-needle approach” or “2-1-1 four-needle approach”, which is more flexible and convenient.

The Group has completed the construction of an iterative-process highly-effective human diploid rabies vaccine workshop that meets international standards, and has completed the production of commercial-scale Phase III clinical trial samples, which is capable of producing this product in large scale.

The human diploid rabies vaccine is the WHO’s gold standard for rabies vaccines, which has been widely applied in many developed countries. As the world’s second largest supplier of rabies vaccines, the Group is committed to leading the in-depth technology iteration and upgrading of rabies vaccines globally and providing the market with a series of rabies vaccine products with better quality and higher safety, thereby promoting the sustainable development of the Group. Obtaining the clinical trial approval for the iterative-process highly-effective human diploid rabies vaccine will further cement the Group’s leading position in global rabies vaccine industry.